Targeting neuroendocrine tumors expressing somatostatin receptor subtypes (sst) with
radiolabeled somatostatin agonists is an established diagnostic and therapeutic approach in …

Earlier studies have shown that modification of the octapeptide octreotide in positions 3 and
8 may result in compounds with increased somatostatin receptor affinity that, if radiolabelled, …

Context: The surgical removal of insulinomas is hampered by difficulties to localize it using
conventional radiological procedures. Recently these tumors were shown to exhibit a very …

Nuclear medicine plays an increasingly important role in the management neuroendocrine
neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission tomography/…

Somatostatin receptor (sstr) scintigraphy for imaging and sstr analogs for treatment have been
used for more than 20 y. An important improvement in recent years was the introduction of …

Somatostatin receptor PET tracers such as [ 68 Ga-DOTA,1-Nal 3 ]-octreotide ( 68 Ga-DOTANOC)
and [ 68 Ga-DOTA,Tyr 3 ]-octreotate ( 68 Ga-DOTATATE) have shown promising …

Preclinical and clinical studies have indicated that somatostatin receptor (sst)–expressing
tumors demonstrate higher uptake of radiolabeled sst antagonists than of sst agonists. In 4 …

Glucagon-like peptide-1 (GLP-1) receptor imaging is superior to somatostatin receptor
subtype 2 (sst 2 ) imaging in localizing benign insulinomas. Here, the role of GLP-1 and sst 2 …

High levels of glucagon-like peptide-1 (GLP-1) receptor expression in human insulinomas
and gastrinomas provide an attractive target for imaging, therapy, and intraoperative tumor …

The precise localization of some insulinomas with the use of conventional imaging techniques
is a challenging clinical problem. These findings indicate that GLP-1–receptor scanning …